Arvinas, Inc. (ARVN): Cash & Equivalents
$142.90M
As of 2025-12-31
$94.30M
As of 2026-06-30
+20.7%
3-year compound annual growth
-24.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $142.90M | +42.2% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $100.50M | -67.8% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $311.70M | +283.4% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $81.30M | -24.9% | 2025-02-11, Balance as of period end |
| 2021-12-31 | $108.30M | -81.6% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $588.40M | n/m | 2023-02-23, Balance as of period end |
| 2019-12-31 | $9.21M | +188.7% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $3.19M | -89.7% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $30.91M | n/a | 2019-03-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $142.90M | +42.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $174.93M | +141.9% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $111.04M | +55.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
Compare ARVN, LGND, SDGR, HROW side by side · Screen every company in Pharmaceutical Preparations ↗